The question isn’t if the science works – but how fast it can scale.
We’re proud to see McKinsey’s Technology Trends Outlook 2025 naming 21st.BIO among the companies shaping the future with groundbreaking technology.
This year’s report highlights 13 frontier technologies transforming global industries – from artificial intelligence and next-generation computing to space tech, robotics, energy and sustainability, and bioengineering.
That’s where we come in.
McKinsey highlights 21st.BIO as a key enabler of large-scale biomanufacturing: “Manufacturing capacity is beginning to scale to match scientific progress. The bioengineering industry is expanding production capacity by installing large-scale infrastructure, such as 2,000-liter bioreactors, to support growing demand and enable broader clinical translation.”
At 21st.BIO, we’re proud to be part of this transformation. Our precision fermentation platform and pilot facility help companies take proteins and biomaterials from lab breakthroughs to industrial-scale production – and we’re going further.
Even with optimal strains and processes, fermentation capacity remains a rate limiting factor. We see scaling rapidly moving from thousands to millions of liters in industrial production to meet global demand.
That’s why we’re working with partners worldwide to establish local and regional fermentation, providing technology which enables attractive business cases. Lack of capacity shouldn’t hold back innovation and the benefits thereof.
The future of biotechnology is being built today – and scaling is a key factor.
